QUANTIFICATION OF METAMORPHOPSIA IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY AFTER HALF-DOSE VERTEPORFIN PHOTODYNAMIC THERAPY
QUANTIFICATION OF METAMORPHOPSIA IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY AFTER HALF-DOSE VERTEPORFIN PHOTODYNAMIC THERAPY
复制标题
DOI：
10.1097/iae.0000000000000027
复制
发表时间：
2014-05-01
影响因子：
3.3
通讯作者：
Yuzawa, Mitsuko
中科院分区：
文献类型：
--
作者：
Fujita, Kyoko;Imamura, Yutaka;Yuzawa, Mitsuko
目的：确定慢性中心性浆液性脉络膜视网膜病变患者接受半剂量维替泊芬光动力治疗前和治疗后1年的视物变形程度。连续45例慢性中心性浆液性脉络膜视网膜病变患者的45只眼进行了评价。在半剂量维替泊芬光动力治疗前和治疗后1、3、6、9和12个月，用M-CHARTS测量视物变形的程度。结果：45只眼中40只眼在1个月时浆液性视网膜脱离完全消退，1只眼在3个月时完全消退，3只眼在6个月时完全消退。一只眼睛的浆液性视网膜脱离在整个随访期间持续存在。平均水平视物变形评分从基线时的0.61 +/- 0.52度显著改善至12个月时的0.49 +/- 0.56度（P = 0.04）。垂直视物变形评分从基线时的0.52 +/- 0.53度显著改善至12个月时的0.33 +/- 0.46度（P = 0.005）。结论：半剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变导致1年时视物变形的显著改善，尤其是基线时具有良好最佳矫正视力的眼睛。半剂量维替泊芬光动力疗法可以作为视力良好但主诉视物变形的患者的治疗选择。
Purpose: To determine the degree of metamorphopsia before and 1 year after half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy.Methods: This was a retrospective, noncomparative, interventional case series. Forty-five eyes of 45 consecutive patients with chronic central serous chorioretinopathy were evaluated. The degree of metamorphopsia was measured with M-CHARTS before and at 1, 3, 6, 9, and 12 months after half-dose verteporfin photodynamic therapy. The best-corrected visual acuity was also measured.Results: Forty of the 45 eyes had a complete resolution of the serous retinal detachment at 1 month, 1 eye at 3 months, and 3 eyes at 6 months. The serous retinal detachment in one eye persisted throughout the follow-up period. The mean horizontal metamorphopsia score improved significantly from 0.61 +/- 0.52 degrees at baseline to 0.49 +/- 0.56 degrees at 12 months (P = 0.04). The vertical metamorphopsia score improved significantly from 0.52 +/- 0.53 degrees at baseline to 0.33 +/- 0.46 degrees at 12 months (P = 0.005).Conclusion: Half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy results in significant improvements of metamorphopsia at 1 year, especially in eyes with good best-corrected visual acuity at the baseline. Half-dose verteporfin photodynamic therapy can be a therapeutic option for patients with good visual acuity who complain of metamorphopsia.